Trump's Team Says Don't Worry About Rising Inflation. Here Are 3 Stocks to Buy If They're Wrong.

The article argues that rising gas prices, up roughly 80% year to date, could fuel broader inflation, but highlights three defensive stocks positioned to withstand that environment: NextEra Energy, Vertex Pharmaceuticals, and Walmart. NextEra is projected to grow EPS at least 8% annually through 2032 and raise its dividend about 10% this year, while Walmart reported 24% year-over-year global e-commerce growth in Q4 and raised its dividend for the 53rd straight year. The piece is largely a stock-picking commentary rather than new company-specific news, so market impact is limited.

Analysis

This is less a broad pro-inflation trade than a selective barbell: cash-flow defensives with pricing power and self-help. If transportation and input costs stay elevated, the second-order winner is not just regulated utilities and staple retailers, but also any business with low elasticity and a credible path to higher nominal revenue per customer. That argues for owning quality defensives while avoiding downstream margin compression in industrials, airlines, and discretionary retail that sit farther from the consumer's ability to absorb sticker shock.

NEE is the cleaner inflation hedge because utility tariffs tend to reprice with a lag but earnings visibility is high and the capex base is inflation-linked. The bigger opportunity is not the dividend; it's the optionality from renewables/storage and the ability to fund growth at scale if capital markets remain orderly. The main risk is duration: if rates re-accelerate, the equity can underperform even if fundamentals hold, so this works best as a relative-value long against rate-sensitive growth or lower-quality yield proxies.

VRTX stands out as a duration-agnostic growth asset with unusually low demand elasticity. The market may be underappreciating how product mix diversification can change the stock's multiple: each incremental non-CF franchise reduces concentration risk and should support a higher terminal multiple, not just earnings growth. The key catalyst path is binary and calendar-driven, with multiple readouts/approvals over the next 12-24 months; the risk is disappointment on execution rather than macro.

WMT is the most direct consumer-share gainer if inflation stays sticky because it can absorb traffic from households trading down while also monetizing digital logistics. The underappreciated angle is that e-commerce share gains improve basket data, fulfillment density, and ad monetization, so inflation can actually widen the moat rather than just defend share. The consensus may be too focused on 'defensive' and not enough on the operating leverage embedded in omni-channel scale.

Key Decisions for Investors

• Long NEE vs. XLU peers on a 3-6 month view: use a 60/40 cash-flow-heavy utility basket hedge to isolate the quality/growth premium; target 8-12% relative upside if inflation remains sticky and power demand stays resilient.
• Buy VRTX on pullbacks and finance with a short in a slower-growth biotech with binary pipeline risk over 6-12 months; asymmetric setup favors VRTX because multiple shots on goal reduce single-asset dependency. Risk: any program setback can compress the multiple quickly.
• Add WMT as a consumer-stress hedge for the next 2-4 quarters; pair against a discretionary retailer or consumer credit proxy to express trade-down behavior. Upside is steady mid-single-digit relative outperformance if fuel/food inflation persists.
• Use call spreads on VRTX rather than outright stock if entering ahead of catalyst windows; this caps theta bleed while keeping exposure to approval/readout upside. Preferred tenor: 6-12 months.
• Avoid chasing NEE as an outright rate hedge if Treasury yields are breaking higher; in that regime, consider a pair long NEE / short a high-duration, low-quality yield name to separate fundamentals from discount-rate noise.